Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a pivotal Phase 3 clinical study ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ‘Phase 3, ...

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Cambridge, Massachusetts Friday, October 24, 2025, 18:00 Hrs [IST] ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody ...